Curis (CRIS) Announces Presentation of Data from Dose-Escalation CUDC-907 Phase 1
Tweet Send to a Friend
Curis (Nasdaq: CRIS) presented data from the completed dose escalation and ongoing expansion stages of the Phase 1 trial of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
